Document Detail

Low-dose oral methotrexate treatment in chronic progressive multiple sclerosis.
MedLine Citation:
PMID:  11603629     Owner:  NLM     Status:  MEDLINE    
We aimed to further assess the safety and efficacy of low-dose oral methotrexate (LDOM) treatment for chronic progressive MS (CPMS). We studied 20 CPMS patients, including 16 with secondary progressive MS who had shown disease progression in the previous year. The mean follow-up was 23 months. The mean EDSS score was 6.3+/-1.1 before treatment and 6.4+/-1.1 after one year of treatment. At one year, 15 of 20 patients were still being treated, and 10 were stable. Twelve patients have completed 18 months of treatment, and eight are stable. Two patients stopped treatment because of side effects, two more because they did not perceive benefit, and one was lost to follow-up. Six patients had mild, transient increases in liver enzymes not requiring treatment interruption, and two had localized herpes zoster. Magnetic resonance imaging (MRI) performed before treatment and at one year remained unchanged in responders. We confirm that LDOM is safe in carefully selected and monitored CPMS patients. MTX is inexpensive and, given its anti-inflammatory and immunomodulatory properties, may be used as add-on therapy in non-responders to interferon beta, although hepatic toxicity may be a problem in long-term treatment.
A Lugaresi; C Caporale; D Farina; F Marzoli; L Bonanni; P A Muraro; G De Luca; C Iarlori; D Gambi
Related Documents :
7774099 - A prospective study of the long-term efficacy and toxicity of low-dose methotrexate in ...
23741689 - Antiadhesive effect and safety of oxidized regenerated cellulose after thyroidectomy: a...
23379449 - Introduction of an n-acetylcysteine weight-based dosing chart reduces prescription erro...
23881089 - Spontaneous rectus sheath hematomas: when to restart anticoagulation?
24350569 - Preliminary experience with stenting for management of non-urolith urethral obstruction...
4017309 - Plasmapheresis vs total lymphoid irradiation in the treatment of severe rheumatoid arth...
21030199 - Open abdominal aortic aneurysm repair is feasible and can be done with excellent result...
9778329 - Potential benefit from implantable cardioverter-defibrillator therapy in patients with ...
389929 - Transiliac lengthening of the lower extremity. a modified innominate osteotomy for the ...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology     Volume:  22     ISSN:  1590-1874     ISO Abbreviation:  Neurol. Sci.     Publication Date:  2001 Apr 
Date Detail:
Created Date:  2001-10-17     Completed Date:  2002-04-17     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  100959175     Medline TA:  Neurol Sci     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  209-10     Citation Subset:  IM    
Department of Oncology and Neuroscience, Gabriele d'Annunzio University, Chieti, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Dose-Response Relationship, Drug
Immunosuppressive Agents / administration & dosage*,  adverse effects
Magnetic Resonance Imaging
Methotrexate / administration & dosage*,  adverse effects
Middle Aged
Multiple Sclerosis, Chronic Progressive / drug therapy*,  pathology,  physiopathology
Treatment Outcome
Reg. No./Substance:
0/Immunosuppressive Agents; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  To treat or not to treat the person with clinical multiple sclerosis--a dilemma.
Next Document:  International connections among midwives.